Under a collaboration agreement, the firms plan to put together Agilent's SLIMS laboratory information system and MGI's DNBSeq series of sequencing platforms.
The company said it will use the funds to support development of its structure for lossless ion manipulation (SLIM) ion mobility separations technology.
Due out in December, the Magnis automated library prep instrument is meant to be an affordable and easy way for researchers to use Agilent's SureSelect kits.
Akadeum is currently developing a tool that involves microbubbles to deplete background molecules from circulating tumor cells in liquid biopsies.
Last week's SynBioBeta conference was indicative of the high degree of interest in the synthetic bio space from omics research tool vendors.
The incubator, housed on the campus of the Karolinska Institute, draws upon the experience of its partners in genomics, diagnostics, business development, and corporate law.
Under the deal, Mobilion is implementing its SLIM ion mobility technology on Agilent's QTOF mass specs, with a broad commercial launch planned for 2021.
The company plans to use the proceeds to fund the redemption of its outstanding 5.00 percent senior notes due 2020.
The firm's diagnostics and genomics group saw an 11 percent year-over-year revenue increase in the third quarter.
Vermont-based BioTek is a privately held company that manufactures and sells life science instruments, including cell imaging systems.
Stephen Hahn, the nominee to lead the US Food and Drug Administration, underwent a Senate confirmation hearing yesterday, the Washington Post reports.
The US Food and Drug Administration has approved an RNA interference drug to treat acute hepatic porphyria.
Gizmodo looks over the past decade of consumer DNA testing to find the field to be lacking.
In Nature this week: native RNA sequencing and analysis of a human poly(A) transcriptome, nanopore sequencing-based method to analyze short tandem repeat expansions, and more.